Al-Batran SE, et al. - For subjects with locally advanced, resectable tumors, researchers tested the safety and effectiveness of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy. In this controlled, open-label, phase 2/3 trial 716 patients were randomly assigned to treatment in 38 German hospitals or with practice-based oncologists between August 8, 2010 and February 10, 2015. According to findings, perioperative FLOT improved overall survival vs perioperative ECF/ECX in locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma (50 months vs 35 months).